Article
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
All News
Article
As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.
Dr. John Cush
Tweet
Evolution of GCA Treatments - More to Come by Meral El Ramahi ( @MeralElRamahiMD) #ACR20
Reflecting on the innovative treatment approach to Giant Cell Arteritis (GCA)
https://t.co/xuQ7Litn8t https://t.co/4NtVSMOPsS
Dr. John Cush
Tweet
GCA Treatment Data: Dr. David Liew Abstract ( @drdavidliew)
Dr. David Liew reviews abstracts #0516 and #0513 presented at the #ACR20 annual meeting.
https://t.co/KmjTRmDbA1
Dr. John Cush
Tweet
Read our article titled: Best Imaging Techniques for non ANCA Vasculitis by Dr. Alexa Meara ( @lexmeara) as discussed at #ACR20
https://t.co/kwXUhn8QSG https://t.co/OjTtFE6jEt
k dao
Tweet
Dr P Seo notes based on PEXIVAS study while PLEX does not seem to help with AAV, it showed you can drop steroid dose sooner: start pred 1 mg/kg/d but drop down after 1 week to 0.5 mg/kg/d #ACRReview #ACR20 @rheumnow
Elizabeth Graef
Tweet
And we're off! #ACR20 year in review
⭐️@philseo's #Vasculitis lecture⭐️
Take home lessons/ remaining questions from GiACTA ⬇️
#ACRambassador https://t.co/7C9QxbUeNH
Elizabeth Graef
Tweet
📌More #Vasculitis pearls from #ACR20 Year in Review
#PEXIVAS in a nutshell ⬇️
#ACRambassador https://t.co/PnoP7QIiYs
Chris Wincup
Tweet
There are a number of important mimics of IgG4-RD that should be considered
🔵ANCA-associated vasculitis
🔵Multicentric Castleman’s disease
🔵Rosai-Dorfman disease
🔵Inflammatory myofibroblastic tumour
🔵Cutaneous plasmacytosis
🔵Erdheim-Chester disease
🔵Malignancy
#ACR20
sheila
Tweet
TAK & GCA differ in vessel involvement when it comes to the 👁👁
> TAK- large vessel lesions
> GCA- small vessel vasculitis
@RheumNow #ACR20 https://t.co/sa4VEvCKOt
Olga Petryna
Tweet
@RheumNow #ACR20 abs1923 prosp cohort study of angiographic lesions in Takayasu’ &GCA: although infrequent new angio lesions more likely in TAK. Improvement is possible in both conditions, more likely to occur in TAK. Change in the branch arteries more dynamic than in the aorta https://t.co/2KsZ6o3vtP
David Liew
Tweet
Mavrilimumab (anti-GM-CSF) in GCA, phase 2
GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying??
PNL induction then enrol+PNL taper
GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62%
Enormous potential, worth exploring!
Cid et al #ACR20 ABSTL06 @RheumNow https://t.co/mq5sTVGbPs
David Liew
Tweet
Can you give TCZ for GCA with minimal steroids?
Everyone hates steroids, right?
GUSTO trial: IVMP 500mg x3d +TCZ sc q1w
14/18 achieved clinical remission at 24w (but mean 11w)
13/18 relapse-free
1/18 permanent visual loss
Is that tradeoff worth it?
#ACR20 ABST0515 @RheumNow https://t.co/H9rgSxL6VP
David Liew
Tweet
Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow
David Liew
Tweet
RITZAREM
(RTX vs AZA maintenance post RTX induction relapsing AAV)
what happened post-study?
After #ACR19, hope RTX confers ongoing benefit
Answer: no. Same decline
Is 1g q4m dosing not justified?
Does that mean RTX needs to be continued, and in whom?
#ACR20 ABST2052 @RheumNow https://t.co/tldGqca8xC
Bella Mehta
Tweet
VEXAS! Hot topic of the year #ACR2020 ABS#1953 @RheumNow https://t.co/RIQKsoWbHe
Mrinalini Dey
Tweet
RITAZAREM trial long-term follow-up
-RTX vs AZA after RTX-induced remission in ANCA #vasculitis
-RTX superior to AZA to prevent relapse
-Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period
Abs#2052 #ACR20 @RheumNow
https://t.co/bW7IaMnVCG
Sebastian E. Sattui MD, MS
Tweet
L06: Mavrilimumab in #GCA
⭐️Efficacy and safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA
Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV
Sustained remission➡️ 33% ⬆️ in MAV
No diff in new or relapsing/ref pts,
No diff in AE
#ACR20 #ACRambassador
Mrinalini Dey
Tweet
SLR comparing the 4-dose ANCA #vasculitis (AAV) rituximab regimen (widely used in RCTs) to 2-dose #rheumatoidarthritis RTX regimen (common in clinical practice), to induce AAV remission, finds no difference in efficacy or safety.
Abs#2048 #ACR20 @RheumNow
https://t.co/WBaWN9d8vs
David Liew
Tweet
The avacopan story, stronger again:
(recall: avacopan targets C5aR)
endogenous anti-C5aR1 in GPA inversely correlates with dx activity, relapse
questions, via chair @philseo:
What happens to anti-C5aR1 with Rx?
Does this influence therapeutic strategy?
#ACR20 ABST2050 @RheumNow https://t.co/g4JfjQal8R
